A novel irreversible and selective BTK inhibitor, ameliorates rheumatoid arthritis by dual inhibition of BCR and osteoclastogenic signaling

	A novel irreversible and selective BTK inhibitor, ameliorates rheumatoid arthritis by dual inhibition of BCR and osteoclastogenic signaling
	Liu, Y.; Lin, Z.; He, S.; Zuo, J.
刊名	EUROPEAN JOURNAL OF IMMUNOLOGY
	2019-10-01
卷号	49 页码:1857-1857
ISSN号	0014-2980
WOS研究方向	Immunology
语种	英语
出版者	WILEY
WOS记录号	WOS:000490026906099
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/281808]
专题	中国科学院上海药物研究所
作者单位	Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Liu, Y.,Lin, Z.,He, S.,et al. A novel irreversible and selective BTK inhibitor, ameliorates rheumatoid arthritis by dual inhibition of BCR and osteoclastogenic signaling[J]. EUROPEAN JOURNAL OF IMMUNOLOGY,2019,49:1857-1857.
APA	Liu, Y.,Lin, Z.,He, S.,&Zuo, J..(2019).A novel irreversible and selective BTK inhibitor, ameliorates rheumatoid arthritis by dual inhibition of BCR and osteoclastogenic signaling.EUROPEAN JOURNAL OF IMMUNOLOGY,49,1857-1857.
MLA	Liu, Y.,et al."A novel irreversible and selective BTK inhibitor, ameliorates rheumatoid arthritis by dual inhibition of BCR and osteoclastogenic signaling".EUROPEAN JOURNAL OF IMMUNOLOGY 49(2019):1857-1857.